Skip to main content
Figure 2 | BMC Women's Health

Figure 2

From: Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia

Figure 2

Cost-effectiveness thresholds for raloxifene treatment of postmenopausal women at varying ages, T-score, and risk of breast cancer. Patient populations with a T-score worse or a breast cancer risk greater than that shown at each line would be considered cost-effective at the indicated societal willingess-to-pay. The influence of age is demonstrated by showing the $50,000/QALY threshold at 60 and 70 years of age.

Back to article page